Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Canadian Agency for Drugs and Technologies in Health ×

Canadian Agency for Drugs and Technologies in Health

This funder is selected. Its supporting articles are shown below.

Canadian Agency for Drugs and Technologies in Health1

Articles mentioning Canadian Agency for Drugs and Technologies in Health

1 articles · page 1 of 1

2SPD-021 Indirect comparison of first-line treatment with tislelizumab, atezolizumab or durvalumab for patients with extensive-stage small-cell lung cancer

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

78.4%

European Commission Canadian Agency for Drugs and Technologies in Health Tislelizumab durvalumab atezolizumab

…rvival benefits. Tislelizumab has been recently approved by the European Commission, but head-to-head comparisons among available immunotherapies a…

Browse funders

Canadian Agency for Drugs and Technologies in Health

Articles mentioning Canadian Agency for Drugs and Technologies in Health

2SPD-021 Indirect comparison of first-line treatment with tislelizumab, atezolizumab or durvalumab for patients with extensive-stage small-cell lung cancer